COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors

Keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cuSCCs) develop in 15–30% of patients with BRAFV600E metastatic melanoma treated with BRAF inhibitors (BRAFi). These lesions resemble mouse skin tumors induced by the two‐stage DMBA/TPA skin carcinogenesis protocol; in this protocol BRAF...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Escuin-Ordinas, Helena, Atefi, Mohammad, Fu, Yong, Cass, Ashley, Ng, Charles, Huang, Rong Rong, Yashar, Sharona, Comin-Anduix, Begonya, Avramis, Earl, Cochran, Alistair J., Marais, Richard, Lo, Roger S., Graeber, Thomas G., Herschman, Harvey R., Ribas, Antoni
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2013
Teme:
Research Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3943738/
https://ncbi.nlm.nih.gov/pubmed/24345644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.11.005
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items